GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » Other Operating Expense

Valneva SE (Valneva SE) Other Operating Expense : $-22.7 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Valneva SE Other Operating Expense?

Valneva SE's Other Operating Expense for the three months ended in Mar. 2024 was $-3.2 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-22.7 Mil.

Valneva SE's quarterly Other Operating Expense declined from Sep. 2023 ($-3.2 Mil) to Dec. 2023 ($-4.9 Mil) but then increased from Dec. 2023 ($-4.9 Mil) to Mar. 2024 ($-3.2 Mil).

Valneva SE's annual Other Operating Expense increased from Dec. 2021 ($-26.0 Mil) to Dec. 2022 ($-13.0 Mil) but then declined from Dec. 2022 ($-13.0 Mil) to Dec. 2023 ($-23.4 Mil).

Valneva SE Other Operating Expense Historical Data

The historical data trend for Valneva SE's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Other Operating Expense Chart

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.04 -23.26 -26.01 -13.00 -23.44

Valneva SE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.73 -11.41 -3.20 -4.88 -3.17

Valneva SE Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valneva SE Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Valneva SE's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Valneva SE (Valneva SE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » Other Operating Expense
Comparable Companies
XPAR:MEDCL XPAR:NANO XPAR:ALSEN XPAR:IPH XPAR:AELIS XPAR:ALCLS XPAR:GNFT XPAR:IVA XPAR:TNG XPAR:ADOC OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
INRLF:USA VLA:France AYJ:Germany VLA:Austria
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Website
https://www.valneva.com
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.